Literature DB >> 31250259

Real-world efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.

Francesco Violi1, Daniele Pastori2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31250259     DOI： 10.1007/s11739-019-02135-y

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  21 in total

1.  Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).

Authors:  Emily C O'Brien; DaJuanicia N Simon; Larry A Allen; Daniel E Singer; Gregg C Fonarow; Peter R Kowey; Laine E Thomas; Michael D Ezekowitz; Kenneth W Mahaffey; Paul Chang; Jonathan P Piccini; Eric D Peterson
Journal:  Am Heart J       Date:  2014-07-11       Impact factor: 4.749

2.  Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial.

Authors:  Michael Böhm; Michael D Ezekowitz; Stuart J Connolly; John W Eikelboom; Stefan H Hohnloser; Paul A Reilly; Helmut Schumacher; Martina Brueckmann; Stephan H Schirmer; Mario T Kratz; Salim Yusuf; Hans-Christoph Diener; Ziad Hijazi; Lars Wallentin
Journal:  J Am Coll Cardiol       Date:  2015-06-16       Impact factor: 24.094

3.  Changes in renal function in patients with atrial fibrillation: Efficacy and safety of the non-vitamin K antagonist oral anticoagulants.

Authors:  Kazuo Miyazawa; Daniele Pastori; Gregory Y H Lip
Journal:  Am Heart J       Date:  2018-01-04       Impact factor: 4.749

4.  Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: Meta-analysis.

Authors:  Ronpichai Chokesuwattanaskul; Charat Thongprayoon; Tanyanan Tanawuttiwat; Wisit Kaewput; Pavida Pachariyanon; Wisit Cheungpasitporn
Journal:  Pacing Clin Electrophysiol       Date:  2018-04-23       Impact factor: 1.976

5.  Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients.

Authors:  José Miguel Rivera-Caravaca; Vanessa Roldán; María Asunción Esteve-Pastor; Mariano Valdés; Vicente Vicente; Gregory Y H Lip; Francisco Marín
Journal:  Thromb Haemost       Date:  2017-03-23       Impact factor: 5.249

6.  Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis.

Authors:  Gregory Y H Lip; Allison Keshishian; Shital Kamble; Xianying Pan; Jack Mardekian; Ruslan Horblyuk; Melissa Hamilton
Journal:  Thromb Haemost       Date:  2016-08-19       Impact factor: 5.249

7.  Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study.

Authors:  Stefan H Hohnloser; Edin Basic; Michael Nabauer
Journal:  Thromb Haemost       Date:  2019-03-21       Impact factor: 5.249

8.  Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis.

Authors:  Craig I Coleman; Reinhold Kreutz; Nitesh A Sood; Thomas J Bunz; Daniel Eriksson; Anna-Katharina Meinecke; William L Baker
Journal:  Am J Med       Date:  2019-05-02       Impact factor: 4.965

9.  Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation.

Authors:  Xiaoxi Yao; Navdeep Tangri; Bernard J Gersh; Lindsey R Sangaralingham; Nilay D Shah; Karl A Nath; Peter A Noseworthy
Journal:  J Am Coll Cardiol       Date:  2017-11-28       Impact factor: 24.094

10.  Exposure to vitamin k antagonists and kidney function decline in patients with atrial fibrillation and chronic kidney disease.

Authors:  Florian Posch; Cihan Ay; Herbert Stöger; Reinhold Kreutz; Jan Beyer-Westendorf
Journal:  Res Pract Thromb Haemost       Date:  2019-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.